Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8166496 | 0.85 | BAZ2B (0.44) | ALDH1A1LMNAKMT2ACYP19A1BAZ2B | |
| SCHEMBL3139376 | 0.80 | KRAS (0.52) | ALDH1A1LMNAKMT2AKRASCYP19A1 | |
| SCHEMBL3142174 | 0.80 | ALDH1A1 (0.46) | ALDH1A1LMNAKMT2ACYP19A1MAPT | |
| SCHEMBL31426002 | 0.78 | KRAS (0.38) | ALDH1A1LMNAKMT2AKRASCYP19A1 | |
| SCHEMBL20738891 | 0.75 | ALDH1A1 (0.44) | ALDH1A1LMNAKRASMAPT | |
| SCHEMBL10840363 | 0.73 | ABCG2 (0.52) | ALDH1A1ATM | |
| SCHEMBL4685270 | 0.73 | NR4A2 (0.57) | ALDH1A1LMNAKMT2ACYP19A1MAPT | |
| SCHEMBL3138279 | 0.72 | GABRG2 (0.45) | ALDH1A1LMNAKMT2AKRASCYP19A1 | |
| SCHEMBL20723187 | 0.71 | CLK1 (0.39) | ALDH1A1LMNAKMT2AKRASCYP19A1 | |
| SCHEMBL30460425 | 0.71 | CLK1 (0.39) | ALDH1A1LMNAKMT2AKRASCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125683-B1 | 3-BENZOFURANYL-4-INDOLYL-MALEIMIDES AS POTENT GSK-3 INHIBITORS FOR NEURODEGENERATIVE DISORDERS | UNIV ILLINOIS (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2125683-B1 | 3-BENZOFURANYL-4-INDOLYL-MALEIMIDES AS POTENT GSK-3 INHIBITORS FOR NEURODEGENERATIVE DISORDERS | UNIV ILLINOIS (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8207216-B2 | Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207216-B2 | Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207216-B2 | Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-01-07 | — | — | US | disclosed |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-01-07 | — | — | US | disclosed |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-01-07 | — | — | US | disclosed |
| EP-2125683-A1 | 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS | The Board of Trustees of the University of Illinois (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077138-A1 | 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008077138-A1 | 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | GSK3B, GSK3A, GSKIP | ALDH1A1 2460/4885LMNA 747/4885KMT2A 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.